Showing results (951-960 of 962) with videos related to

Sort By:
Pageof 97
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Immunogenetics|June 17, 1999
MIC-A allele profiles and HLA class I associations in Behçet's diseaseG R Wallace, D H Verity, L J Delamaine, et al.
British Journal of Cancer|August 14, 2014
MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancerS Hasegawa, H Eguchi, H Nagano, et al.
The British Journal of Ophthalmology|August 30, 2008
Microsatellite analysis of the GLC1B locus on chromosome 2 points to NCK2 as a new candidate gene for normal tension glaucomaM Akiyama, K Yatsu, M Ota, et al.
Breast Cancer Research and Treatment|March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)H Kawaguchi, N Masuda, T Nakayama, et al.
Genomics|May 15, 1997
Nucleotide sequence analysis of the HLA class I region spanning the 237-kb segment around the HLA-B and -C genesN Mizuki, H Ando, M Kimura, et al.
Breast Cancer Research and Treatment|October 15, 2013
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapyS Ohno, L W C Chow, N Sato, et al.
Breast Cancer Research and Treatment|April 1, 2014
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)M Takada, H Ishiguro, S Nagai, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Investigation of the association between the GLC3A locus and normal tension glaucoma in Japanese patients by microsatellite analysisM Kamio, A Meguro, M Ota, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Pageof 97